From 'MEFTAL' to 'MEFIAL': Why a One-Letter Change and Copied Packaging Led to Heavy Costs in a Landmark Pharmaceutical Trademark Battle at the Bombay High Court.

🔒 For Members Only

Case: BLUE CROSS LABORATORIES PRIVATE LIMITED v. ALTO HEALTHCARE PRIVATE LIMITED AND ANOTHER
Court: Bombay High Court
Date: 17-06-2026
Law: Trade Marks Act, Copyright Act, Code of Civil Procedure, Commercial Courts Act, Indian Evidence Act.

Full Judgment → MCQ Test →

In the high-stakes world of pharmaceutical branding, the difference between a trusted remedy and a deceptive imitation often hangs by a single letter. A recent judgment by the Bombay High Court in Blue Cross Laboratories Private Limited v. Alto Healthcare Private Limited serves as a masterclass in how Indian courts view intellectual property (IP) protection, especially when public health is on the line. The case centered on the well-known analgesic "MEFTAL-SPAS" and a competitor's attempt to enter the market with the strikingly similar "MEFIAL-SPAS".

For businesses and legal practitioners, this ruling is more than just a victory for a major brand; it is a roadmap for navigating the complexities of deceptive similarity, trade dress, and the evolving regime of litigation costs in commercial disputes.

1. The "One-Letter" Fallacy

One of the most striking aspects of this case was the Defendants' attempt to bypass trademark law by merely substituting the letter "T" with the letter "I". The court was unimpressed. It reaffirmed that trademark infringement is not a game of "spot the difference". When the core of a coined word is lifted, a minor typographical variation does not negate the deceptive similarity.

The court noted that such a slight change is specifically designed to exploit the "imperfect recollection" of the average consumer. In the pharmaceutical sector, where consumers often rely on memory or handwritten prescriptions, this phonetic and visual overlap is particularly dangerous.

2. The Totality of Trade Dress

The judgment emphasizes that a trademark does not exist in a vacuum. The Defendants didn't just copy the name; they "lifted" the entire visual identity of the product. This included the red and blue color scheme, the geometric bordering, and the specific layout of the tablet strips.

"Comparison of the rival products makes it plain that the impugned mark and the artistic work are deceptively similar to the Plaintiff’s trade marks and artistic work. It is clear that the Defendants have also copied the blue and red colour scheme packaging..."

This reinforces the principle that "Trade Dress"—the total image and appearance of a product—is a vital component of IP that courts will protect vigorously to prevent "passing off".

3. The Heightened Standard for Pharmaceuticals

A recurring theme in Indian IP jurisprudence, which this judgment strengthens, is that the "likelihood of confusion" test is applied much more strictly to medicinal products. While a confused consumer buying the wrong brand of biscuits is a minor inconvenience, a consumer buying the wrong medicine is a public health risk.

The court highlighted that because these are analgesic and antispasmodic preparations, the potential for deception warrants a stricter judicial eye. This serves as a stern warning to manufacturers: the "close enough" approach to branding will not fly when public safety is at stake.

4. The "Cost" of Dishonesty and Non-Appearance

Perhaps the most impactful takeaway for modern litigators is the court’s application of Section 35 of the Code of Civil Procedure (CPC), as amended by the Commercial Courts Act, 2015. The Defendants chose not to contest the matter after an initial filing, leading to an ex-parte proceeding.

The court utilized its powers to award "compensatory costs" of Rs. 5,00,000 against the Defendants. This wasn't just a nominal fee; it was a calculated move to compensate the Plaintiff for "wholly avoidable expenditure" caused by the Defendants' negligent and dishonest conduct. It signals that the Commercial Courts are increasingly willing to use costs as a tool to deter bad-faith litigation and "copycat" business models.

5. The Evidence Trap: Why Damages Require Proof

Despite the clear-cut infringement, the court denied the Plaintiff's claim for Rs. 1,00,000 in damages. Why? Because the Plaintiff failed to lead specific evidence to quantify the loss. This is a crucial reminder for plaintiffs: a "strong case" for infringement does not automatically translate into a monetary windfall.

While the court awarded costs to cover legal expenses, it maintained a disciplined boundary regarding damages. To recover losses, a brand must prove them with data, not just demonstrate the opponent's dishonesty.

This judgment reinforces the sanctity of "coined" trademarks and the protective umbrella of trade dress. As the Bombay High Court has shown, when a competitor tries to "encash" on another’s goodwill through deceptive similarity, the law will not only halt the infringement but will also ensure the infringer pays for the privilege of the Plaintiff's time in court.